Skip to content
Screener

Edgewise Therapeutics, Inc. EWTX Business Segments — Interest Income Expense Nonoperating Net

Similar metrics at other companies

Dollar General logo
DGSingle Reportable — Interest Income Expense Nonoperating Net
-$47.24M+26.9%
Napco Security Technologies logo
NSSCSingle Reportable — Interest Income Expense Nonoperating Net
$986K+14.4%
Norwegian Cruise Line Holdings Ltd. logo
NCLHSingle Reportable — Interest Income Expense Nonoperating Net
-$165.99M+23.8%
Cracker Barrel Old Country Store logo
CBRLSingle Reportable — Interest Income Expense Nonoperating Net
-$3.67M+26.4%
Anika Therapeutics logo
ANIKSingle Reportable — Interest Income Expense Nonoperating Net
$426K+99.1%
Onto Innovation logo
ONTOSingle Reportable — Interest Income Expense Nonoperating Net
$8.74M+4.4%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.78B+236%
Enterprise value$4.75B+244%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Personnel expense14,72510,624
Stock-based compensation expense8,7159,059
Other segment expense(a)6,1964,464
Depreciation537514
Segment net loss(54,115)(45,959)
Reconciliation of net loss
Interest income5,1025,161
Net Loss$(49,013)$(40,798)

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s business segments — interest income expense nonoperating net?
Edgewise Therapeutics, Inc. (EWTX) reported business segments — interest income expense nonoperating net of $5.1M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s business segments — interest income expense nonoperating net changed year-over-year?
Edgewise Therapeutics, Inc.'s business segments — interest income expense nonoperating net decreased by 1.1% year-over-year, from $5.16M to $5.1M.
What does business segments — interest income expense nonoperating net mean?
Captures the net balance of interest earned on cash and investments versus interest paid on debt obligations. This metric reflects the company's treasury management performance and its reliance on external financing. It is a critical component of non-operating financial health for companies with significant cash reserves.

Ask your AI about Edgewise Therapeutics, Inc.'s business segments — interest income expense nonoperating net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude